• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Am Soc Echocardiogr . Echocardiographic Correlates of In-Hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of

tetano

Editor, Senior Moderator
J Am Soc Echocardiogr


. 2021 May 20;S0894-7317(21)00483-1.
doi: 10.1016/j.echo.2021.05.010. Online ahead of print.
Echocardiographic Correlates of In-Hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study


Ilya Karagodin[SUP] 1 [/SUP], Cristiane Carvalho Singulane[SUP] 1 [/SUP], Gary M Woodward[SUP] 2 [/SUP], Mingxing Xie[SUP] 3 [/SUP], Edwin S Tucay[SUP] 4 [/SUP], Ana C Tude Rodrigues[SUP] 5 [/SUP], Zuilma Y Vasquez-Ortiz[SUP] 6 [/SUP], Azin Alizadehasl[SUP] 7 [/SUP], Mark J Monaghan[SUP] 8 [/SUP], Bayardo A Ordonez Salazar[SUP] 9 [/SUP], Laurie Soulat-Dufour[SUP] 10 [/SUP], Atoosa Mostafavi[SUP] 11 [/SUP], Antonella Moreo[SUP] 12 [/SUP], Rodolfo Citro[SUP] 13 [/SUP], Akhil Narang[SUP] 14 [/SUP], Chun Wu[SUP] 3 [/SUP], Tine Descamps[SUP] 2 [/SUP], Karima Addetia[SUP] 1 [/SUP], Roberto M Lang[SUP] 1 [/SUP], Federico M Asch[SUP] 15 [/SUP], WASE-COVID Investigators



Affiliations

Abstract

Background: The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus which has led to the global Coronavirus disease-2019 (COVID-19) pandemic is known to adversely affect the cardiovascular system through multiple mechanisms. In this international, multi-center study conducted by the World Alliance Societies of Echocardiography (WASE), we aim to determine the clinical and echocardiographic phenotype of acute cardiac disease in COVID-19 patients, to explore phenotypic differences in different geographic regions across the world, and to identify parameters associated with in-hospital mortality.
Methods: We studied 870 patients with acute COVID-19 infection from 13 medical centers in four world regions (Asia, Europe, United States, Latin America) who had undergone transthoracic echocardiograms (TTEs). Clinical and laboratory data were collected, including patient outcomes. Anonymized echocardiograms were analyzed with automated, machine learning-derived algorithms to calculate left ventricular (LV) volumes, ejection fraction (EF), and LV longitudinal strain (LS). Right-sided echocardiographic parameters that were measured included right ventricular (RV) LS, RV free wall strain (FWS), and RV basal diameter (RVBD). Multivariate regression analysis was performed to identify clinical and echocardiographic parameters associated with in-hospital mortality.
Results: Significant regional differences were noted in terms of patient co-morbidities, severity of illness, clinical biomarkers, and LV and RV echocardiographic metrics. Overall in-hospital mortality was 21.6%. Parameters associated with mortality in a multivariate analysis were age (OR 1.12 [1.05, 1.22], p = 0.003), previous lung disease (OR 7.32 [1.56, 42.2], p = 0.015), LVLS (OR 1.18 [1.05, 1.36], p = 0.012), lactic dehydrogenase (LDH) (OR 6.17 [1.74, 28.7], p = 0.009), and RVFWS (OR 1.14 [1.04, 1.26], p = 0.007).
Conclusions: LV dysfunction is noted in approximately 20% and RV dysfunction in approximately 30% of patients with acute COVID-19 illness and portend a poor prognosis. Age at presentation, previous lung disease, LDH, LVLS, and RVFWS were independently associated with in-hospital mortality. Regional differences in cardiac phenotype highlight the significant differences in patient acuity as well as echocardiographic utilization in different parts of the world.

Keywords: COVID-19; Echocardiography; International; Mortality; Strain; WASE.
 
Back
Top Bottom